Cambridge Trust CO Apellis Pharmaceuticals, Inc. Transaction History
Cambridge Trust CO
- $2.6 Billion
- Q1 2024
A detailed history of Cambridge Trust CO transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Cambridge Trust CO holds 11,500 shares of APLS stock, worth $383,180. This represents 0.03% of its overall portfolio holdings.
Number of Shares
11,500
Previous 11,500
-0.0%
Holding current value
$383,180
Previous $688,000
1.89%
% of portfolio
0.03%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding APLS
# of Institutions
308Shares Held
115MCall Options Held
3.85MPut Options Held
1.09M-
Wellington Management Group LLP Boston, MA15.6MShares$519 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$396 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$370 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$327 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$193 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.66B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...